NasdaqGS:ARWRBiotechs
A Look At Arrowhead Pharmaceuticals (ARWR) Valuation As Fisher Builds Stake And SHASTA Readouts Approach
Arrowhead Pharmaceuticals (ARWR) is back in focus after Ken Fisher’s fund increased its holdings and management spotlighted upcoming Phase III SHASTA-3 and SHASTA-4 readouts for plozasiran, which has been flagged as a multibillion dollar commercial opportunity.
See our latest analysis for Arrowhead Pharmaceuticals.
At a share price of US$56.71, Arrowhead has had a 1 month share price return of 11.14% and a year to date share price decline of 16.34%, set against a very large 1 year total...